1. SCHWARZ, T. et al. Immunogenicity and safety of hepatitis B vaccine in adolescents aged 14-15 years, previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/HIB vaccine in infancy. In: ESPID, 36º, 2018, Malmo. Poster. Disponível em: <https://public-poster-links.s3.amazonaws.com/ESPID-2018/ESPID-2018-ESP18-0325.pdf>. Acesso em: 05 jun. 2018.
2. INFANRIX®HEXA [diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed)]. Summary of product characteristics, 2018. Disponível em: <http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/000296/WC500032505.pdf>. Acesso em: 05 jun. 2018.
3. INFANRIX® HEXA [vacina adsorvida difteria, tétano, pertussis (acelular), hepatite B (recombinante), poliomielite 1, 2 e 3 (inativada) e Haemophilus influenzae b (conjugada)]. Bula do produto.
4. WANG, S. et al. A review of Haemophilus influenzae disease in Europe from 2000-2014: challenges, successes and the contribution of hexavalent combination vaccines. Expert Review of Vaccines, 16(11): 1095-1105, 2017.